Prognostic Accuracy of qSOFA, SIRS, and EWSs for In-hospital Mortality in Emergency Department - Trial NCT05172479
Access comprehensive clinical trial information for NCT05172479 through Pure Global AI's free database. This phase not specified trial is sponsored by Aseer Central Hospital and is currently Completed. The study focuses on Sepsis,Septic Shock. Target enrollment is 3274 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Aseer Central Hospital
Timeline & Enrollment
N/A
Dec 12, 2021
Sep 11, 2023
Primary Outcome
In-hospital mortality
Summary
Early identification of a patient with infection who may develop sepsis is of utmost
 importance. Unfortunately, this remains elusive because no single clinical measure or test
 can reflect complex pathophysiological changes in patients with sepsis. However, multiple
 clinical and laboratory parameters indicate impending sepsis and organ dysfunction. Screening
 tools using these parameters can help identify the condition, such as SIRS, quick SOFA
 (qSOFA), National Early Warning Score (NEWS), or Modified Early Warning Score (MEWS). The
 2016 SCCM/ESICM task force recommended using qSOFA, while the 2021 Surviving Sepsis Campaign
 strongly recommended against its use compared with SIRS, NEWS, or MEWS as a single screening
 tool for sepsis or septic shock. We hypothesised that qSOFA has greater prognostic accuracy
 than SIRS and EWS (NEWS/NEWS2/MEWS).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05172479
Non-Device Trial